Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$12.63 USD
+0.19 (1.53%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $12.67 +0.04 (0.32%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Liquidia Technologies, Inc. (LQDA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$27.67 | $32.00 | $23.00 | 122.43% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Liquidia Technologies, Inc. comes to $27.67. The forecasts range from a low of $23.00 to a high of $32.00. The average price target represents an increase of 122.43% from the last closing price of $12.44.
Analyst Price Targets (6 )
Broker Rating
Liquidia Technologies, Inc. currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.71 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 71.43% and 14.29% of all recommendations. A month ago, Strong Buy made up 71.43%, while Buy represented 14.29%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/LQDA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 1 | 1 | 1 |
ABR | 1.43 | 1.43 | 1.71 | 1.71 | 1.71 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/25/2024 | Not Identified | Not Identified | Hold | Hold |
5/15/2024 | LadenburgThalmann | Matthew L Kaplan | Strong Buy | Strong Buy |
4/1/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
3/8/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
12/20/2023 | BTIG | Julian Harrison | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.43 |
ABR (Last week) | 1.43 |
# of Recs in ABR | 7 |
Average Target Price | $27.67 |
LT Growth Rate | 38.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 73 of 252 |
Current Quarter EPS Est: | -0.35 |